BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech has reported a sharp decline in second-quarter revenue and swung to a loss as demand for COVID-19 vaccines fell, sending its shares lower in Monday pre-market trading on the Nasdaq. The German company, which developed a vaccine with Pfizer, reported revenue of €168 million for the period to June 30, 2023, from €3.2 billion a year earlier.

BioNTech stock declines as revenue topples on lower demand for Covid vaccine

Sales drop by more than expected in the second quarter, but BioNTech says its new 'variant-adapted Covid-19 vaccine' is still on track.

BioNTech Stock Falls. The Covid-19 Vaccine Maker Misses Revenue Estimates.

Germany's BioNTech , Pfizer's partner on COVID-19 vaccines, cut its drug development budget for this year after quarterly revenues were hurt by a plunge in pandemic-related demand.

BioNTech reduces drug development spend as COVID vaccine sales plunge

Shares of BioNTech SE BNTX, -0.16% dropped 2.4% toward a three-month low in premarket trading Monday, after the Germany-based biotechnology company, which developed a COVID-19 vaccine with partner Pfizer Inc. PFE, +0.06%, reported second-quarter revenue that fell well short of expectations, while swinging to a net loss that beat forecasts. The company reported a net loss of EUR190.4 million ($208.8 million), or EUR0.79 a share, after net income of EUR1.67 billion, or EUR6.45 a share, in the year-ago period.

BioNTech stock drops after revenue falls well short of expectations, but affirms 2023 COVID vaccine revenue view

Significant pipeline advancement highlighted by the initiation of BNT316/ONC-392 Phase 3 pivotal trial and multiple trials planned to start across the oncology portfolio Positive data updates across multiple technology platforms including ADC candidate BNT323/DB-1303, anti-CTLA4 monoclonal antibody candidate BNT316/ONC-392 and CAR-T candidate BNT211 Preparation for launch of Omicron XBB.1.5-adapted monovalent COVID-19 vaccine as recommended by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and other health authorities; deliveries expected to start as early as September, subject to regulatory approval Reiterates COVID-19 vaccine revenue guidance of approximately €5 billion in 2023 First half1 of 2023 revenues of €1.4 billion2, net profit of €311.8 million and fully diluted earnings per share of €1.28 ($1.383) Conference call and webcast scheduled for August 7, 2023, at 8:00 am EDT (2:00 pm CEST) MAINZ, Germany, August 7, 2023 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three and six months ended June 30, 2023, and provided an update on its corporate progress. “We are progressing our oncology pipeline into late-stage development, having launched a pivotal Phase 3 trial and preparing for additional trials with registrational potential in the coming months,” said Prof.

BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update

Disney

Palantir Technologies

Earnings season rolls along this week, with reports also due from Paramount, Eli Lilly, Wynn Resorts, and many more. And look out for crucial inflation indicators in economic data to be released at week's end.

Disney, UPS, and More Stocks to Watch This Week

A leading immunotherapy innovator with a focus on oncology and infectious diseases. With a strong pipeline and capable management, the company is likely to continue its success in the long run. A projected decline in vaccine revenues is likely to affect upcoming Q2 2023 figures, but the company's profitability outlook remains favorable in the big picture. BioNTech demonstrates an exceptional cash balance while maintaining manageable total liabilities.

BioNTech: Unraveling A Bargain, A Hidden Opportunity In Market Misjudgments

MAINZ, Germany, July 31, 2023 – BioNTech SE  (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of InstaDeep Ltd.  (“InstaDeep”), a leading global technology company in the field of artificial intelligence (“AI”) and machine learning (“ML”). The acquisition was announced on January 10, 2023 and follows a track record of increasing collaboration between the two companies since 2019 as well as BioNTech's initial equity investment as part of InstaDeep's Series B financing round in January 2022.

BioNTech Completes Acquisition of InstaDeep

Moderna

BioNTech and Moderna will likely always be compared due to the phenomenal success of their COVID vaccines. The two companies will report Q2 2023 earnings early next month - revenues may well disappoint the market. Both companies are pinning their hopes on the emergence of a private COVID market, however - which could be worth >$20bn per annum.

BioNTech And Moderna: Fallen Angels Of The COVID Era Are Buys Ahead Of Earnings

MAINZ, Germany , July 24, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2023 on Monday, August 7th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter 2023.

BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy BioNTech (BNTX) Stock?

The mean of analysts' price targets for BioNTech SE Sponsored ADR (BNTX) points to a 40.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in BioNTech SE Sponsored ADR (BNTX)? Wall Street Analysts Think 40.69%

Celularity

Chimerix

Innoviva

Regeneron Pharmaceuticals

Voyager Therapeutics

Zymeworks Inc

Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of success to investors.

Why These 7 Stocks Are the Best Ways to Play Biotech Right Now

BioNTech and its U.S. partner OncoC4 Inc say they have started a late-stage study of their lung cancer immunotherapy candidate as the German COVID-19 vaccine maker seeks to advance its traditional focus on oncology drug development.

BioNTech, OncoC4 start late-stage lung cancer drug trial

MAINZ, Germany, and ROCKVILLE, Maryland, USA, June 29, 2023 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced that the first patient with non-small cell lung cancer (NSCLC) has been treated in a pivotal Phase 3 trial evaluating the companies' next-generation anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart). The trial is part of BioNTech's strategy to initiate multiple pivotal trials in 2023 and 2024.

BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

Pfizer

Pfizer and partner BioNTech said on Friday they have initiated an application to the European Medicines Agency (EMA) for authorization of updated COVID-19 vaccine targeting Omicron subvariant XBB.1.5.

Pfizer/BioNTech initiate application with EU regulator for updated COVID vaccine

BioNTech's Q1 2023 revenues decreased to $1,404.7 million due to a drop in global COVID-19 vaccine sales, but the company has a strong immunotherapy pipeline for future growth. The company's financial metrics show mixed results, with strong profitability and low debt levels but negative stock momentum. Despite the risks and challenges, BioNTech's robust fundamentals, promising pipeline, and commitment to innovation make it a "Buy" recommendation for investors.

BioNTech: Navigating Post-Pandemic Challenges With Innovative Therapies And Bold Strategies

Novavax

The U.S. Food and Drug Administration (FDA) said on Friday it has advised manufacturers that are updating their COVID-19 vaccines to develop monovalent shots to target the XBB.1.5 subvariant.

US FDA advises COVID vaccine makers to develop shots aimed at XBB.1.5 variant

An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.

FDA Panel Endorses Updating COVID Jab to Target XBB Strain

The first hearing in a German court case against BioNTech over alleged side effects of its COVID-19 vaccine was postponed by a court on Monday.

BioNTech vaccine hearing postponed after complaint over bias

BioNTech will go to court on Monday to defend itself against a lawsuit from a German woman who is seeking damages for alleged side effects of its COVID-19 vaccine, the first of potentially hundreds of cases in the country.

BioNTech faces first German lawsuit over alleged COVID vaccine side effects

SentinelOne

Valens Semiconductor Ltd

While the market theoretically prices in all publicly available information for all securities, the sheer volume of opportunities available breathe life into underrated stocks with potential. Put another way, the below enterprises are Wall Street's equivalent of brown guacamole.

3 Ugly Stocks That Actually Hide Beautiful Potential

BioNTech (BNTX) announces positive initial data evaluating BNT316/ONC-392 to treat metastatic non-small cell lung cancer.

BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody

BioNTech's shares have fallen this year, along with its revenue. The company said it expects $5 billion in 2023 revenue from its COVID-19 vaccine, Comirnaty.

Why Shares of BioNTech Rose Friday

BioNTech said Friday almost a third of patients with a hard-to-treat form of lung cancer responded to its treatment — and BNTX stock popped.

News for BioNTech SE Stock (BNTX)